Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D05BBB
|
|||
| Former ID |
DNCL001816
|
|||
| Drug Name |
Saratin
|
|||
| Indication | Inflammation [ICD-11: 1A00-CA43.1] | Phase 2 | [1], [2] | |
| Company |
BioVascular
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | VWF-dependent platelet-collagen conversion (VDDPCC) | Target Info | Inhibitor | [1], [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Antithrombotic effects of saratin on human atherosclerotic plaques. Thromb Haemost. 2004 Jul;92(1):191-200. | |||
| REF 2 | Saratin, an inhibitor of von Willebrand factor-dependent platelet adhesion, decreases platelet aggregation and intimal hyperplasia in a rat carotid endarterectomy model. J Vasc Surg. 2001 Oct;34(4):724-9. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.